With 2020 set to bring the curtain down on a biotech IPO boom unlike anything we’ve seen before, you have to wonder which companies are setting the stage to try and follow up with their own S-1 in 2021. And Locanabio may be in the mix after today.
The San Diego-based biotech just brought in a mega-round, always helpful ahead of any IPO. In this case, that’s $100 million from a slate of investors that’s adding groups with a well-known taste for IPO strategies: Vida Ventures, RA Capital, Invus, Acuta Capital and an investment arm of market maker SVB Leerink. Rajul Jain, an MD who had been on the executive team at Kite b